Evidence map›Paper›PMID 30209959›Full record

ArticleThe British journal of radiology2019

Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans.

Hesheng Wang, Benjamin T Cooper, Peter Schiff, Nicholas J Sanfilippo, S Peter Wu, Kenneth S Hu, Indra J Das, Jinyu Xue

Abstract read
In one paragraph

Article in The British journal of radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hesheng WangDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
Benjamin T CooperDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
Peter SchiffDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
Nicholas J SanfilippoDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
S Peter WuDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
Kenneth S HuDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
Indra J DasDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.
Jinyu XueDepartment of Radiation Oncology, NYU Langone Health & Laura and Isaac Perlmutter Cancer Center , New York, NY , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective: Radiobiological models have been used to calculate the outcomes of treatment plans based on dose-volume relationship. This study examines several radiobiological models for the calculation of tumor control probability (TCP) of intensity modulated radiotherapy plans for the treatment of lung, prostate, and head and neck (H&N) cancers.

methods: Dose volume histogram (DVH) data from the intensity modulated radiotherapy plans of 36 lung, 26 prostate, and 87  H&N cases were evaluated. The Poisson, Niemierko, and Marsden models were used to calculate the TCP of each disease group treatment plan. The calculated results were analyzed for correlation and discrepancy among the three models, as well as different treatment sites under study.

results: The median value of calculated TCP in lung plans was 61.9% (34.1-76.5%), 59.5% (33.5-73.9%) and 32.5% (0.0-93.9%) with the Poisson, Niemierko, and Marsden models, respectively. The median value of calculated TCP in prostate plans was 85.1% (56.4-90.9%), 81.2% (56.1-88.7%) and 62.5% (28.2-75.9%) with the Poisson, Niemierko, and Marsden models, respectively. The median value of calculated TCP in H&N plans was 94.0% (44.0-97.8%) and 94.3% (0.0-97.8%) with the Poisson and Niemierko models, respectively. There were significant differences between the calculated TCPs with the Marsden model in comparison with either the Poisson or Niemierko model (p < 0.001) for both lung and prostate plans. The TCPs calculated by the Poisson and Niemierko models were significantly correlated for all three tumor sites.

conclusion: There are variations with different radiobiological models. Understanding of the correlation and limitation of a TCP model with dosimetric parameters can help develop the meaningful objective functions for plan optimization, which would lead to the implementation of outcome-based planning. More clinical data are needed to refine and consolidate the model for accuracy and robustness. ADVANCES IN KNOWLEDGE:: This study has tested three radiobiological models with varied disease sites. It is significant to compare different models with the same data set for better understanding of their clinical applicability.

Indexed as

Models, BiologicalRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedHead and Neck NeoplasmsHumansLung NeoplasmsMaleProbabilityProstatic NeoplasmsRadiotherapy Dosage

Identifiers

PMID30209959
PMCPMC6404826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.